As Medicare's GLP-1 Bridge program gets underway in earnest and questions remain about the long-term use of these drugs, Eli Lilly is offering a new look at how older adults fare on its medication, Zepbound.
As Medicare's GLP-1 Bridge program gets underway in earnest and questions remain about the long-term use of these drugs, Eli Lilly is offering a new look at how older adults fare on its medication, Zepbound.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
As Medicare's GLP-1 Bridge program gets underway in earnest and questions remain about the long-term use of these drugs, Eli Lilly is offering a new look at how older adults fare on its medication, Zepbound.
Open the app view to save this story, compare related coverage, and continue from the same source.